



Professor, DMSc Thomas J. Vogl  
Institut für Diagnostische und Interventionelle Radiologie  
Goethe Universität  
Theodor-Stern-Kai 7  
Haus 23c60590 Frankfurt am Main  
Germany  
e-mail: t.vogl@em.uni-frankfurt.de

7 July 2009  
j.no. 7-203-07-1/1/CME

Dear Professor, DMSc Thomas J. Vogl

Being a small country, Denmark has profound interest in international collaboration and exchange of experience within the health services. The Danish Health Care System is constantly looking for possible innovations in order to ensure development and introduction of new treatment modalities as early as possible. At the same time it is very important for us that scientific evidence is collected systematically so that evidence based guidelines can be made and evidence based decisions taken regarding diagnoses, treatment, and care.

During the last years, an increasing number of Danish patients with hepatic metastases from various types of cancers have travelled to your clinic to receive treatment.

In order to advise patients the best possible way, the Danish National Board of Health needs documented scientific evidence on the treatment in question.

Therefore, the Danish National Board of Health has decided to obtain more detailed knowledge about the treatment you offer to Danish patients both with respect to efficacy and safety.

The Danish National Board of Health therefore by this letter kindly requests you to submit information on the following issues:

1. Could you please state your criteria for inclusion of patients for intrahepatic chemotherapy, especially regarding patients with extrahepatic metastases as well.
2. On which criteria are the cancer drugs for intrahepatic chemotherapy chosen for the various types of cancer?
3. Are the results of intrahepatic chemotherapy collected according to a particular scientific protocol ensuring a systematic collection of scientific evidence?

**Health Planning**  
**National Board of Health**  
Islands Brygge 67  
DK- 2300 København S  
Phone +45 72 22 74 00  
Fax +45 72 22 74 05  
E-mail info@sst.dk

Dir. ph. +45 7222 7647  
E-mail efp@sst.dk

4. Are Danish patients offered intrahepatic chemotherapy as part of a scientific protocol?
5. Do you have any scientific evidence from randomized trials indicating that intrahepatic chemotherapy of hepatic metastases for each of the cancer types in question offers advantages to patients as compared to systemic exposure with chemotherapy?

Page 2  
7 July 2009

**National Board of Health**

The information from you would be of importance for the Danish National Board of Health and the Danish Health System in general in order to satisfactorily assist and advise Danish cancer patients who may wish to consider receiving treatment abroad.

Looking forward to your reply, and thanking you in advance for your kind cooperation.

Yours sincerely,

Hans von der Maase  
Professor of Oncology and Clinical Cancer Research, MD, DMSc

Lone de Neergaard  
Head of Department of Health Planning, MD